Licensing status

Publication and contact information

Renal disease

Renal disease

MicroRNA-193a (miR-193a)

Patient tissue and mouse studies suggest antagonizing miR-193a could help treat focal segmental glomerulosclerosis (FSGS), which can lead to renal failure. Patients with FSGS showed greater expression of miR-193a in glomeruli than healthy individuals. In mice, transgenic expression of miR-193a induced FSGS pathology. Next steps include testing the effects of targeting miR-193a with locked RNA in a mouse model.

SciBX 6(15); doi:10.1038/scibx.2013.372
Published online April 18, 2013

Patent application filed; available for licensing

Gebeshuber, C.A. et al. Nat. Med.; published online March 17, 2013;
Contact: Dontscho Kerjaschki, Medical University of Vienna, Vienna, Austria